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A B S T R A C T
While right ventricle to pulmonary artery homograft is the surgical procedure of choice for relieving right ventricle
outﬂow tract obstruction; it is limited by the need for multiple surgical replacements owing to progressive conduit
obstruction, valve dysfunction, or patient growth. Since January 2010, percutaneous transcatheter placement of
prosthetic pulmonary valve (Melody valve) has emerged as an attractive alternative to surgical replacement of
dysfunctional right ventricle to pulmonary artery homograft in the United States. We report a case of 19-year-old
girl born with truncus arteriosus who underwent transcatheter placement of prosthetic pulmonary valve due to
homograft insufﬁciency. She presented after 4 months with a febrile episode and was found to have Staphylococcus
aureus endocarditis of her prosthetic valve. The infection caused multi-organ dysfunction despite bacteriological
clearance and led to severe dysfunction of the valve which ultimately required surgical removal. The case highlights
a rare but serious complication of percutaneous prosthetic pulmonary valves.
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Introduction
Surgical placement of a right ventricle (RV) topulmonary artery (PA) homograft has become
the procedure of choice for palliation of RV
outﬂow tract obstruction in many forms of
complex congenital heart disease.1 Homograft
placement is, however, limited by the need for
surgical replacement owing to progressive conduit
obstruction, valve dysfunction, or patient
growth.1,2 Prolongation of the conduit life may be
achieved with bare metal stent placement, though
this comes at the cost of creating free conduit
insufﬁciency.3 Transcatheter placement of percu-
taneous prosthetic pulmonary valve (Melody
valve, Medtronic Corp., Minneapolis, MN, USA)
was introduced in the year 2000 in some parts of
the world as an attractive and safe alternative to
surgical revision of the RV-PA conduit.4,5 The US
Food and Drug Administration (FDA) approved
the use of Melody Transcatheter Pulmonary Valve
on January 25, 2010.6 We describe a case of poten-
tially life-threatening infective endocarditis (IE)
involving Melody valve implanted at our center.
Case Report
A 19-year-old girl with repaired truncus arteriosus
presented to the emergency room with complaints
of vomiting and diarrhea. She denied fever, any
exposure to sick contacts, or recent dental or gyne-
cological procedures.
Her medical history was signiﬁcant for repair of
truncus arteriosus in infancy with placement of a
RV to PA homograft and patch closure of the
ventricular septal defect (VSD). The conduit was
replaced twice due to progressive stenosis. At the
age of 3 years, she underwent surgical augmenta-
tion of her conduit along with placement
of a transannular patch. While she remained
asymptomatic from cardiovascular standpoint, her
echocardiogram at 18 years, showed free conduit
insufﬁciency with moderate to severe dilatation of
the RV which was conﬁrmed on a subsequent
cardiac magnetic resonance imaging (MRI) with
indexed RV end diastolic volume of 167.4 mL/m2.Disclosures: None.
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For relief of her pulmonary insufﬁciency, she
underwent placement of a Melody valve using a
22 mmEnsemble delivery system4months prior to
the presentation. The post procedure and 3-month
follow-up echocardiograms did not reveal any sig-
niﬁcant regurgitation or stenosis of the Melody
valve.
Upon admission, the patient was febrile (tem-
perature 38.8°C) with tachycardia of 130 beats/
minute, blood pressure of 120/77 mm Hg,
respiratory rate of 21 breaths/minute, and satura-
tions of 97% on room air. Her cardiovascular
examination showed normal heart sounds with a
grade 3/6, medium-pitched, ejection systolic
murmur heard best at the left parasternal area.
There was no hepatosplenomegaly. Her initial
laboratory tests were signiﬁcant for thrombocy-
topenia (platelet count of 37 000/mm3) and
hyponatremia (sodium 126 meq/L). An ultrasound
of the abdomen and pelvis did not show any
abscesses.
Her blood cultures showed immediate growth
of Staphylococcus aureus for which she was started
on vancomycin and ceftriaxone, which were sub-
sequently replaced with oxacillin after the organ-
ism was found to be Methicillin-sensitive (MSSA).
Her urine and stool cultures from admission also
grew MSSA and the blood cultures remained posi-
tive for 7 days after starting antibiotics.
Transthoracic echocardiography (TTE) per-
formed at the time of admission showed a new
ﬁnding of mild to moderate conduit stenosis
(maximum PA pressure gradient = 46 mm Hg) and
elevated RV systolic pressures (RVSP) to 3/4th
systemic (77 mm Hg). The Melody valve did not
show any regurgitation or vegetations. Due to per-
sistently positive blood cultures, a repeat trans-
esophageal echocardiogram was performed on day
8 of admission, which showed worsening of RV
function, increasing RVSP (87 mm Hg) and wors-
ening conduit stenosis (maximum PA gradient of
62 mm Hg). Also, a linear vegetation in the proxi-
mal part of RV conduit was visualized (Figure 1).
The gradient across RV-PA conduit was signiﬁ-
cantly increased (maximum PA gradient estimated
as 62 mm Hg) compared to post–Melody valve
placement hemodynamics (20 mm Hg) raising
possible concerns for a Melody valve stent frac-
ture. This was subsequently ruled out under ﬂuo-
roscopic interrogation.
Despite achieving bacterial clearance, the
patient continued to show clinical deterioration.
She developed clinical signs of disseminated intra-
vascular coagulopathywith INRof 3.1, aPTTof 52
seconds and PT of 33 seconds along with renal
failure due to immune mediated glomerulonephri-
tis. Her serum creatinine increased to 2.4 mg/dL
with proteinuria (2+) and hematuria (3+).Her renal
function further deteriorated and she required
hemodialysis for about 1 week. She also developed
worsening pulmonary edema. Her echocardio-
grams showed severe depression of LV and RV
function with. elevated RVSP (90 mm Hg). She
was started on intravenous inotropes and aggres-
sive diuretic therapy. Over the next 2 weeks, her
repeat blood cultures remained negative, her clini-
cal status improved with resolution of renal failure
and she was weaned off of inotropic support. Two
months after the initial presentation, she under-
went surgical removal of the Melody valve and
placement of a valved RV-PA conduit. She was
doing well at 7 months follow-up.
Discussion
Prosthetic valves are a known risk factor for IE.
Correa de Sa et al. conducted a population based
survey of IE in Minnesota from 1970 to 2006.7 A
total of 150 cases of IE were identiﬁed among the
adult population, of which 33 (22%) involved a
prosthetic valve. Few large studies conducted on
incidence of IE in children reveal lower rates of
IE when compared to adults. Day et al. reviewed
multi-centric data on 1588 children admitted with
IE.8 A prosthetic valve was the site of infection in
Figure 1. Transesophageal echocardiogram showing the
prosthetic pulmonary valve (upper arrow) and a linear
thread-like vegetation in the proximal right ventricle to pul-
monary artery conduit (bottom arrow).
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54 patients (3.4%) and the infection was fatal in
7.4% of patients. The most common site of pros-
thetic valve involvement was the aortic valve fol-
lowed by the mitral valve. IE has rarely been
reported in surgically placed prosthetic pulmonary
valves. Rosenthal et al. studied 72 children with
known heart disease who developed IE between
1992 and 2004 at a single center.9 Seven patients
(10%) developed IE in surgically placed prosthetic
pulmonary valve. Among 64 pediatric patients
who had surgical implantation of RV-PA conduit
with prosthetic bovine pulmonary valve,10 Shebani
et al. reported one patient with endocarditis
within 2 weeks of surgery due to Staphylococcus
aureus who required valve explantation.
Transcatheter percutaneous pulmonary valve
(Melody valve) implantation was introduced in the
year 2000 in some parts of the world as an attractive
and safe alternative to surgical revision of the
RV-PA conduit. The Melody valve is made from a
cow’s jugular vein valve that is sewn into a small
metal stent (scaffolding). While there is not much
long-term data on Melody valves from the United
States, reports from outside the country indicate
that Melody valve is not a common site of involve-
ment for IE. In a review of 155 patients from
United Kingdom who underwent Melody valve
placement (aged between 7 to 71 years), Lurz et al.
reported endocarditis in only ﬁve patients
(0.03%).4 The pathogens included staphylococcus
aureus, streptococcus species and Candida. Three
patients required valve explantationwhile twowere
treated successfully medically. Eicken et al. found
that among 102 patients (aged 16–30 years) in
Germany who underwent Melody valve place-
ment,5 only one patient developed Staphylococcus
aureus endocarditis after 6 months which required
valve explantation and replacement with
homograft. Butera et al. studied 63 patients from
Italy (aged 11–65 years) who underwent Melody
valve placement from 2007 to 2010.11 Two patients
developed IE and needed surgical explant. In a
multi-centric study by Roberts et al. 15 patients
(aged 8–64 years) underwent transcatheter implan-
tation of percutaneous tricuspid valve,12 one of
whomdeveloped endocarditis.None of the authors
have reported serious life-threatening complica-
tions from endocarditis as seen in our patient.
In our center, among 35 patients who have
undergone transcatheter implantation of Melody
valve one developed potentially life-threatening
IE. To our knowledge, this is the ﬁrst reported
case of IE involving the Melody valve from the
United States. Our patient developed late onset
endocarditis of the Melody valve 4 months after
valve implantation. An aggressive Staphylococcus
aureus infection of the valve led to rapidly progres-
sive ventricular dysfunction in this patient with
subsequent multi-organ failure despite bacterio-
logical clearance. The most likely port of entry of
the bacteria was through gastrointestinal tract,
which then seeded the valve leading to endocardi-
tis of the prosthesis. The infection ﬁnally led to
the surgical removal of the Melody valve and
placement of a RV-PA conduit.
Our case highlights a rare but important com-
plication of percutaneous prosthetic pulmonary
valves. Melody valve has recently been introduced
in the United States, and the long-term data on
complications are not yet available. However, the
delay of 4 months between the placement of
Melody valve and onset of IE in our patient
indicates that the IE was not related to the cath-
eterization procedure or technique. Further lon-
gitudinal follow-up studies would help in assessing
the overall risk, incidence, and outcome of IE in
these patients. Our report, conﬁrms the AHA rec-
ommendation that patients should be advised IE
prophylaxis after implantation of the Melody
valve.13 A high index of suspicion should be main-
tained for IE in these patients similar to those with
mechanical or surgically placed prosthetic valves.
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